Avalo Therapeutics Inc
F:C6K0
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Avalo Therapeutics Inc
F:C6K0
|
US |
|
G
|
General Electric Co
DUS:GCP
|
US |
|
C
|
Continental AG
DUS:CON
|
DE |
|
D
|
Danaher Corp
BMV:DHR
|
US |
|
S
|
Smurfit Kappa Group PLC
XMUN:SK3
|
IE |
|
A
|
Avery Dennison Corp
DUS:AV3
|
US |
|
B
|
Bangkok Commercial Asset Management PCL
SET:BAM
|
TH |
Wall St Price Targets
C6K0 Price Targets Summary
Avalo Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for C6K0 is 35.25 EUR with a low forecast of 26.08 EUR and a high forecast of 47.85 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is C6K0's stock price target?
Price Target
35.25
EUR
According to Wall Street analysts, the average 1-year price target for C6K0 is 35.25 EUR with a low forecast of 26.08 EUR and a high forecast of 47.85 EUR.
What is the Revenue forecast for Avalo Therapeutics Inc?
Projected CAGR
227%
Over the last 13 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 8 years is 227%.
What is the Gross Profit forecast for Avalo Therapeutics Inc?
Projected CAGR
221%
The compound annual growth rate for Gross Profit over the next 8 years is 221%.
